Health Affairs This Week The Great Health Care Vision Board (Stacie Dusetzina)
Jan 21, 2026
Stacie Dusetzina, a health policy researcher at Vanderbilt specializing in drug pricing and insurance policy. She dissects the Trump administration's Great Healthcare Plan as vision-board rhetoric with few details. She explains most-favored-nation pricing, limits of transparency, OTC drug shifts, insurer finance disclosures, and HSA affordability risks in short, clear takes.
AI Snips
Chapters
Transcript
Episode notes
Most Favored Nations Limits And Caveats
- Most favored nations aims to get U.S. drug prices similar to other countries by benchmarking against them.
- Stacie Dusetzina warns grandfathering negotiated voluntary deals may exclude many commonly used drugs from impact.
Transparency Alone Rarely Lowers Costs
- Price transparency and other buzzwords sound appealing but often fail to lower consumer costs in practice.
- Dusetzina emphasizes implementation details matter and past transparency efforts haven't moved the needle.
Avoid Overreliance On Consumer Shopping
- Don’t rely on consumers to price-shop as a primary cost-control strategy.
- Dusetzina notes most people lack tools and ability to shop effectively for lower-cost care.